Research programme: hyperlipidaemia therapeutics - IntelGenx Corp/Circ PharmaAlternative Names: CRES pravastatin; Versatab
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator Circ Pharma; IntelGenx Corp.
- Class Naphthalenes
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperlipidaemia in France (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperlipidaemia in Ireland (PO, Tablet)